IP Library Granted Patent US 11,512,075
Granted Patent B2
US 11,512,075 · App. 16/622,111 · Granted Nov 29, 2022

Synthesis of 20-nor-salvinorin A

Inventors: Ryan Shenvi (San Diego, CA); Jeremy Roach (San Diego, CA); Yusuke Sasano (Sendai, JP); Laura Bohn (Jupiter, FL); Cullen Schmid (Cambridge, MA)
Assignee: The Scripps Research Institute
C07D407/04A61P17/04C07C69/757C07D307/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,512,075
App. No.
16/622,111
Granted
Nov 29, 2022
Kind
B2
Abstract

The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.

Claims (6)

1. A compound of formula 20-nor-salvinorinA

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

3. A method of modulating a kappa-opioid receptor, comprising contacting the kappa-opioid receptor with an effective amount or concentration of a compound of claim 1 .

4. A method of treating a medical condition in a patient, wherein modulation of a kappa-opioid receptor is medically indicated, comprising administering to the patient an effective dose of the compound of claim 1 .

5. The method of claim 4 , wherein the medical condition is selected from pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness.

6. A method for treatment of a medical condition in a patient, comprising administering to the patient an effective dose of the compound of claim 1 , wherein the medical condition is selected from pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness.

Assignments (1)
CONFIRMATORY LICENSE Recorded Feb 6, 2020
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 051836/0362 →
Continuity (2)
Provisional Application 62519363 · Jun 14, 2017
Related Publication 20200131162A1 · Apr 30, 2020